PRDM16 and acute myeloid leukemia: Clinically favorable-risk groups, such as AML with inv(16), t(8;21), and CEBPAbZIPinf, showed low PRDM16 copy numbers, while AML with NUP, UBTF-TD and t(6;9) exhibited significantly higher PRDM16 read counts.